Gilead Sciences (GILD) Dividends Paid - Common Growth (1y) (2016 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Div. Paid (Common) Growth (1y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
15.01% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
4.75% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
5.50% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
2.68% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
6.18% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
3.59% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
0.33% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
1.99% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
3.59% |
| Dec 31, 2025 |
2.16% |
| Sep 30, 2025 |
1.84% |
| Jun 30, 2025 |
1.94% |
| Mar 31, 2025 |
2.45% |
| Dec 31, 2024 |
2.96% |
| Sep 30, 2024 |
2.52% |
| Jun 30, 2024 |
2.52% |
| Mar 31, 2024 |
1.14% |
| Dec 31, 2023 |
1.50% |
| Sep 30, 2023 |
2.14% |
| Jun 30, 2023 |
2.36% |
| Mar 31, 2023 |
3.97% |
| Dec 31, 2022 |
4.14% |
| Sep 30, 2022 |
3.09% |
| Jun 30, 2022 |
3.21% |
| Mar 31, 2022 |
1.64% |
| Dec 31, 2021 |
2.41% |
| Sep 30, 2021 |
4.50% |
| Jun 30, 2021 |
4.27% |
| Mar 31, 2021 |
4.92% |
| Dec 31, 2020 |
8.04% |
| Sep 30, 2020 |
7.31% |
| Jun 30, 2020 |
6.91% |
| Mar 31, 2020 |
7.37% |
| Dec 31, 2019 |
9.78% |
| Sep 30, 2019 |
8.18% |
| Jun 30, 2019 |
8.43% |
| Mar 31, 2019 |
8.24% |
| Dec 31, 2018 |
7.92% |
| Sep 30, 2018 |
9.38% |
| Jun 30, 2018 |
9.85% |
| Mar 31, 2018 |
9.46% |
| Dec 31, 2017 |
10.18% |
| Sep 30, 2017 |
9.47% |
| Jun 30, 2017 |
8.63% |
| Mar 31, 2017 |
17.04% |
| Dec 31, 2016 |
0.81% |
| Sep 30, 2016 |
-1.27% |
| Jun 30, 2016 |
-2.03% |
